These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

701 related items for PubMed ID: 8301131

  • 1. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 2. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 3. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H, Chang AE, Shu SY.
    Cancer Res; 1992 Mar 01; 52(5):1129-36. PubMed ID: 1531321
    [Abstract] [Full Text] [Related]

  • 4. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 5. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1994 May 15; 54(10):2744-50. PubMed ID: 8168105
    [Abstract] [Full Text] [Related]

  • 6. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1993 Sep 15; 53(18):4315-21. PubMed ID: 8364926
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of superantigen-induced "anergy" on priming and effector stages of a T cell-dependent antibody response.
    Lussow AR, MacDonald HR.
    Eur J Immunol; 1994 Feb 15; 24(2):445-9. PubMed ID: 8299694
    [Abstract] [Full Text] [Related]

  • 9. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
    Shimizu M, Yamamoto A, Nakano H, Matsuzawa A.
    Cancer Res; 1996 Aug 15; 56(16):3731-6. PubMed ID: 8706016
    [Abstract] [Full Text] [Related]

  • 10. Acquired resistance to superantigen-induced T cell shock. V beta selective T cell unresponsiveness unfolds directly from a transient state of hyperreactivity.
    Miethke T, Wahl C, Heeg K, Wagner H.
    J Immunol; 1993 May 01; 150(9):3776-84. PubMed ID: 8473732
    [Abstract] [Full Text] [Related]

  • 11. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 12. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K, Chang AE, Shu SY.
    Cancer Res; 1990 Jul 15; 50(14):4371-6. PubMed ID: 2114215
    [Abstract] [Full Text] [Related]

  • 13. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen.
    Kuroda K, Yagi J, Imanishi K, Yan XJ, Li XY, Fujimaki W, Kato H, Miyoshi-Akiyama T, Kumazawa Y, Abe H, Uchiyama T.
    J Immunol; 1996 Aug 15; 157(4):1422-31. PubMed ID: 8759722
    [Abstract] [Full Text] [Related]

  • 14. T cells made deficient in interleukin-2 production by exposure to staphylococcal enterotoxin B in vivo are primed for interferon-gamma and interleukin-10 secretion.
    Florquin S, Amraoui Z, Goldman M.
    Eur J Immunol; 1995 May 15; 25(5):1148-53. PubMed ID: 7774618
    [Abstract] [Full Text] [Related]

  • 15. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
    Dohlsten M, Björklund M, Sundstedt A, Hedlund G, Samson D, Kalland T.
    Immunology; 1993 Aug 15; 79(4):520-7. PubMed ID: 7691731
    [Abstract] [Full Text] [Related]

  • 16. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H, Shu S.
    J Immunol; 1998 Apr 01; 160(7):3444-52. PubMed ID: 9531305
    [Abstract] [Full Text] [Related]

  • 17. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
    Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE.
    J Immunol; 1997 Jul 15; 159(2):664-73. PubMed ID: 9218581
    [Abstract] [Full Text] [Related]

  • 18. Study of activation of murine T cells with bacterial superantigens. In vitro induction of enhanced responses in CD4+ T cells and of anergy in CD8+ T cells.
    Yan XJ, Li XY, Imanishi K, Kumazawa Y, Uchiyama T.
    J Immunol; 1993 May 01; 150(9):3873-81. PubMed ID: 8097227
    [Abstract] [Full Text] [Related]

  • 19. In vivo tumor immunotherapy by a bacterial superantigen.
    Ochi A, Migita K, Xu J, Siminovitch K.
    J Immunol; 1993 Sep 15; 151(6):3180-6. PubMed ID: 8376773
    [Abstract] [Full Text] [Related]

  • 20. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
    Shu S, Sussman JJ, Chang AE.
    J Immunother Emphasis Tumor Immunol; 1993 Nov 15; 14(4):279-85. PubMed ID: 8280709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.